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Abstract:  The objective of this  study  was  to  investigate the salivary  proteins  that  are 
associated with periodontitis in patients with Type 2 diabetes mellitus (T2DM). Volunteers 
for the study were patients from the Diabetic Unit, University of Malaya Medical Centre, 
whose periodontal status was determined. The diabetic volunteers were divided into two 
groups, i.e., patients with periodontitis and those who were periodontally healthy. Saliva 
samples were collected and treated with 10% TCA/acetone/20 mM  DTT to precipitate  
the  proteins,  which  were  then  separated  using  two-dimensional  polyacrylamide  gel 
electrophoresis. Gel images were scanned using the GS-800
TM Calibrated Densitometer. 
The protein spots were analyzed and expressed in percentage volumes. The percentage 
volume  of  each  protein  spot  was  subjected  to  Mann-Whitney  statistical  analysis  using 
SPSS software and false discovery rate correction. When the expression of the salivary 
proteins was compared between the T2DM patients with periodontitis with those who were 
periodontally  healthy,  seven  proteins,  including  polymeric  immunoglobulin  receptor, 
plastin-2,  actin  related  protein  3,  leukocyte  elastase  inhibitor,  carbonic  anhydrases  6, 
immunoglobulin J and interleukin-1 receptor antagonist, were found to be differentially 
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expressed (p < 0.01304). This implies that the proteins may have the potential to be used as 
biomarkers for the prediction of T2DM patients who may be prone to periodontitis. 
Keywords: periodontitis; type 2 diabetes mellitus; salivary protein; 2-DE 
 
1. Introduction 
Diabetes mellitus  is  a major global  health problem and it has  an increasing  prevalence due to 
several factors, such as population growth, aging, urbanization and increasing prevalence of obesity or 
lack of physical exercise. The number of people diagnosed with diabetes is increasing at an alarming 
rate. It is estimated that by the year 2030, 366 million people worldwide will have the disease [1]. 
Based on the Diabetes Atlas [2], the highest numbers of patients are currently found mainly in western 
countries, such as in the European region and the Western Pacific region. This, however, will change 
in the year 2025 where the greatest number of diabetic patients is expected to be from the Asian  
region  [2,3].  In  Malaysia,  Ministry  of  Health  studies  estimate  that  the  number  of  people  having 
diabetes was more than 10% of the total population (26.64 millions) in 2006 [4], and that this number 
is estimated to increase every year. In the US alone, at least 8.3% of the total population has diabetes 
mellitus with 18.8 million people diagnosed, and an estimated further 7 million undiagnosed. Diabetes 
mellitus is the seventh leading cause of death in the US. In Malaysia, it was estimated that for the year 
2000, at least 2261 deaths were caused by diabetes mellitus [5]. 
Diabetes mellitus is the leading cause of heart disease, stroke, hypertension, blindness and other eye 
problems, kidney disease, amputation and oral diseases. Periodontitis has been considered as the sixth 
complication  of  type  2  diabetes  mellitus  (T2DM)  after  retinopathy,  nephropathy,  neuropathy, 
cardiovascular disease and peripheral vascular disease [6]. It had been reported in several studies that 
patients with T2DM have an increased risk of periodontitis [7–9]. Periodontitis is an inflammatory 
disease  of  the  periodontium,  primarily  caused  by  bacterial  infection  [10].  In  advanced  cases  of 
periodontitis, degradation of the connective tissue and destruction of the bone occur, ultimately leading 
to tooth loss in adults [11]. Current evidence shows that diabetes and persisting hyperglycemia will 
lead to exaggerated immune-inflammatory response to the periodontal bacterial challenges, which will 
result in more rapid and severe periodontal tissue destruction [10]. 
Poor  metabolic  control  as  well  as  an  extended  period  of  diabetic  status  are  risk  factors  for 
periodontitis when abundant dental biofilm is present on the teeth [8]. Grossi et al., [12] have reported 
that effective management of periodontal infection by utilizing systemic antibiotics can be beneficial 
to diabetic patients. These antibiotics will reduce the local signs and symptoms of periodontitis as well 
as improve the diabetic status of the patient. They recommend that control of periodontal disease can 
lead to improvement of the diabetic status of the patient. In the National Oral Health Survey of adults 
undertaken  by  the  Oral  Health  Division,  Ministry  of  Health,  Malaysia  [13],  there  was  a  high 
prevalence of periodontal disease in the adult population. About 90% of the population aged between 
45 and 70 apparently had periodontal problems. 
To date, there is no data from any studies regarding patients with diabetes and periodontitis using 
the  proteomic  approach.  In  this  study,  the  profiles  of  proteins  in  saliva  samples  from  volunteers Int. J. Mol. Sci. 2012, 13  4644 
 
 
suffering  from  T2DM  with  periodontitis  were  compared  with  those  of  diabetics  with  a  healthy 
periodontium. Saliva, and not blood, was chosen as the sample used in the study, as many reports have 
suggested that saliva can be an alternative to blood [2]. Saliva contains a large number of proteins 
which have metabolic, immune response, transporting and several other cellular functions [14–18].  
Its collection is non-invasive compared to the collection of other body fluids, and hence has a great 
potential for use in the diagnosis of systemic and localized diseases. The proteins in the saliva samples 
were separated using two-dimensional polyacrylamide gel electrophoresis (2-DE) method and analyzed 
for any differential expression which may have the potential as predicting factors for the development 
of periodontitis in T2DM individuals.  
2. Results and Discussion 
Human whole saliva contains fluids, mainly from the salivary glands as well as contributions from 
the gingival crevicular fluid, oral tissues, epithelial cells, bronchial and nasal secretions, and traces of 
blood,  bacteria  and  viruses.  Compared  to  serum,  whole  saliva  is  consistently  under  the  influence  
of  a  hostile  environment,  with  its  proteins  subjected  to  changes  and  modifications  by  host-  and  
foreign-derived enzymes [19]. This results in the possible generation and modifications of proteins in 
whole saliva. 
In the present study, dry strips of 11 cm length and pH range of 4 to 7 were used. This range of pH 
was  chosen  as  most  of  the  saliva  proteins  were  resolved  in  acidic  pH  between  4  to  7  [20].  
The 2-DE profiles of whole saliva  proteins  from  T2DM  patient  volunteers  with  periodontitis  and 
T2DM patients with healthy periodontium that were generated in this study (Figure 1) showed a strong 
resemblance to those which were previously reported [20–24]. This is most likely due to similarities in 
the subjects that were involved in the studies (race, age range and inclusion and exclusion criteria) as 
well as the methodology that was used. By comparing the 2-DE profiles generated in this study with 
those  reported  by  Jessie  et  al.  [23],  most  of  the  proteins  could  be  identified.  There  were  
42 highly resolved spots that could be matched to a total of 23 different proteins (Table 1). 
Table  1.  Densitometry  analysis  of  saliva  proteins  and  their  rates  of  presence  in  
protein profiles. 
Proteins 
Protein 
Label 
Diabetes with 
Periodontitis % 
Volume 
a (± SEM) 
RP 
b/15 
Diabetes with 
Healthy 
Periodontium % 
Volume 
a (± SEM) 
RP 
b//10 
Serotransferrin  1  2.602 (± 1.274)  15  3.430 (± 1.254)  10 
pIgR  2  5.093 (± 1.591)  15  6.848 (± 1.273)  10 
Plastin 2  4  0.434 (± 0.161)  15  0.182 (± 0.039)  8 
Alpha-1-antitrypsin  6  1.858 (± 0.641)  15  1.818 (± 0.836)  10 
Protein disulfide 
isomerase 
7  0.230 (± 0.090)  14  0.199 (± 0.093)  8 
Actin-related protein 3  8  0.023 (± 0.004)  14  0.135 (± 0.088)  9 Int. J. Mol. Sci. 2012, 13  4645 
 
 
Table 1. Cont. 
Proteins 
Protein 
Label 
Diabetes with 
Periodontitis % 
Volume 
a (± SEM) 
RP 
b/15 
Diabetes with Healthy 
Periodontium % 
Volume 
a (± S.E.M) 
RP 
b//10 
Zinc-alpha-2-glycoprotein 
9 
3.816 (± 1.236)  15  3.735 (± 0.671)  10 
11 
12 
13 
Actin beta 
10 
1.567 (± 0.584)  15  1.913 (± 0.883)  10  16 
17 
Leukocyte elastase 
inhibitor 
14  0.386 (± 0.162)  14  0.201 (± 0.126)  9 
Carbonic anhydrase VI  15  1.665 (± 0.595)  14  2.273 (± 0.549)  10 
Complement C3  18  0.582 (± 0.278)  15  0.626 (± 0.268)  10 
SPLUNC 
19 
2.193 (± 0.962)  12  1.117 (± 0.776)  9  20 
21 
Annexin A3  22  0.199 (± 0.098)  15  0.133 (± 0.091)  8 
Ig Kappa chain c region  23  23.031 (± 3.968)   15  17.870 (± 8.369)  10 
Immunoglobulin J chain  24  2.402 (± 0.338)  15  1.378 (± 1.706)  10 
Glutathione S Transferase  25  0.369 (± 0.252)  15  0.270 (± 0.112)  10 
Prolactin inducible protein 
26 
6.362 (± 2.176)  15  4.648 (± 1.388)  10 
27 
28 
32 
33 
34 
Lipocalin -1 
29 
1.948 (± 0.926)  15  1.602 (± 0.455)  10 
30 
31 
35 
37 
Interleukin-1 receptor 
antagonist protein 
36  0.041 (± 0.016)  15  0.171 (± 0.060)  9 
Haptoglobin 
38 
0.397 (± 0.246)  15  0.578 (± 0.323)  10  39 
40 
Transthyretin 
41 
0.213 (± 0.125)  13  0.215 (± 0.145)  5 
42 
a volume of a protein expressed as a percentage of the total protein spots in a single particular 2-DE profile;  
b RP—rate of presence for particular protein spots in the total 2-DE profiles that were analyzed. Int. J. Mol. Sci. 2012, 13  4646 
 
 
Figure 1. Typical 2-DE profile of human saliva protein. Comparisons were made with the 
one published by Jessie et al. [23] and the protein spots were suspected to be those as listed 
in Table 1. 
 
Analysis by densitometry detected the differential expression of seven salivary proteins between the 
two groups of T2DM patients. This include protein immunoglobulin J (IGJ) chain (+1.743; p < 0.001), 
polymeric immunoglobulin receptor (pIgR) (−1.344; p = 0.008), plastin-2 (PLS2) (+2.381; p < 0.001), 
actin-related protein (Arp) (−5.802; p = 0.001), interleukin-1 receptor antagonist (IL-1ra) (−4.132;  
p < 0.001), leukocyte elastase inhibitor (LEI) (+1.919; p = 0.004) and carbonic anhydrase VI (CA VI) 
(−1.365; p = 0.012) (Table 2).  Int. J. Mol. Sci. 2012, 13  4647 
 
 
Table 2. List of proteins that were differentially expressed. 
Proteins  Fold Change 
a  p-Value 
PIGR  −1.344  0.008 
Plastin 2  +2.381  0 
Actin-related protein 3  −5.802  0.001 
Leukocyte elastase inhibitor  +1.919  0.004 
Carbonic anhydrase VI  −1.365  0.012 
Immunoglobulin J chain  +1.743  0 
Interleukin-1 receptor antagonist  −4.132  0 
a Fold change is the ratio of % volume of T2DM patients with periodontitis to T2DM patients with 
healthy periodontium. 
IGJ exhibited an increase of 1.7-fold expression in the T2DM patients with periodontitis compared 
to the controls. The IGJ chain is an 18 kDa protein. It is produced and excreted by  mucosal and 
glandular plasma cells which regulate the polymer formation of IgA [25] and IgM [26–28]. IGJ helps 
these  immunoglobulins  to  bind  to  the  secretory  component.  It  provides  the  polymeric  
IgA  and  pentameric  IgM  with  the  capacity  to  bind  pIgR  and  this  subsequently  regulates  the  pIg 
structure [26,28]. The pIgR mediates the active transport of bound pIg from the basolateral to the 
apical  face  of  exocrine  epithelial  cells,  thus  releasing  secretory  antibodies  to  the  mucosal  
surfaces [26,28]. This may provide an explanation for the high levels of IGJ in the saliva from the 
T2DM patients with periodontitis. Secretory IgA (sIgA) and secretory IgM antibodies, which serve as 
the first line of specific immunologic defense, are actively transported to the mucosal secretions via the IGJ. 
Contrariwise, pIgR appears to be down-regulated in T2DM patients with periodontitis. This is not 
quite  understood.  Nevertheless,  studies  have  shown  that  proteins  may  be  recycled,  degraded  or 
transcytosed to the opposite surface after delivery to one surface [29]. 
In this study, the expression of plastin-2 (PLS2) was found to be higher in the T2DM patients with 
periodontitis compared to the group with healthy periodontium. This observation is in agreement with 
the report of Bostanci et al. [30], which suggests that PLS2 is associated with periodontitis. PLS2, 
which is also known as L-plastin (LCP1), has a role in the regulation of leukocyte adhesion [31], 
suggesting  that  many  signaling  events  implicated  in  integrin  regulation  activities  via  induction  of  
L-plastin phosphorylation [32]. PLS2 belongs to the actin-binding protein family, which is found in cells 
of hematopoetic origin, such as leukocytes. It has been reported that the high concentration of this 
protein in gingival crevicular fluid (GCF) facilitates recruitment of polymorphonuclear neutrophils 
(PMN) at sites of inflammation. This is in agreement with the report on the potential constitutive PMN 
hyper-reactivity in non-diabetic volunteers with periodontitis [30]. In another study, it was shown that 
there was a reduction in PLS2 in the GCF of non-diabetic volunteers with gingivitis, suggesting that 
there is a less adherent phenotype in neutrophils during the stage of inflammatory response [33]. 
Leukocyte elastase inhibitor (LEI) is a 43 kDa protein that was also shown to be up-regulated in 
patients with T2DM who had periodontitis in this study. LEI is a naturally occurring inhibitor of 
neutrophil proteases [34]. The imbalance of proteases and their natural inhibitors due to the excess 
release  by  neutrophils  and  monocytes  is  thought  to  be  responsible  for  tissue  injury  in  human 
inflammatory diseases such as respiratory disease, joint inflammation, sepsis and skin diseases [35]. 
LEI has been reported to function as a physiological inhibitor of the proteases that are important in the Int. J. Mol. Sci. 2012, 13  4648 
 
 
immune  defense  but  when  present  in  excess,  they  function  as  major  agents  of  inflammation  by 
destroying  matrix  proteins  as  well  as  immune  defense  molecules.  The  higher  amount  of  LEI  in 
diabetics with periodontitis observed in this study suggests that this protein may be responsible for 
further destruction of the periodontium, matrix proteins, further lowering the immune defense system 
and subsequently, destruction of the alveolar bone. 
The CO2-carbonic acid-bicarbonate system is responsible for most of the buffering capacity in the 
human whole saliva. The salivary glands are able to produce bicarbonate from CO2, yielding salivary 
bicarbonate levels that are usually slightly lower than plasma levels [36]. Carbonic anhydrases (CAs) 
catalyze the reversible reaction of CO2 + H2O ↔ HCO3
− + H
+. There are several carbonic anhydrase 
isoenzymes, with CA II and CA VI being mainly expressed in human salivary glands, where CA VI is 
secreted  in  the  saliva  [37–39].  A  recent  study  had  shown  that  the  low  level  of  salivary  CA  VI 
expression is associated with an increased risk of caries [39]. It has been reported that the saliva CA VI 
accumulates in the enamel pellicle maintaining its enzymatic activity, and that it may catalyze the 
neutralization of the acid produced by bacteria, thus providing an immune defense locally on tooth 
surfaces [39]. The lower level of CA VI that was observed in the T2DM patients with periodontitis 
suggests its higher risk in the development of caries and possibly periodontitis. 
Actin-related protein 3 (Arp3) functions as an ATP binding component of the Arp2/3 complex [40]. 
In the present study, Arp 3 appeared to have lower expression in T2DM patients with periodontitis 
compared to the controls. Arp2/3 complex builds a network of actins to help the movement of immune 
cells  and  enables  them  to  guard  against  bacterial  infection  [41,42].  When  production  of  Arp3  is 
lowered, the binding of ATP to produce the Arp2/3 complex is also reduced, making the host more 
susceptible to infection.  
The  higher  expression  of  interleukin-1  receptor  antagonist  (IL-1Ra)  in  the  T2DM  group  with 
healthy periodontium suggests its possible role in protecting the periodontium from the inflammatory 
effect of IL-1. IL-1 is a type of proinflammatory protein that inhibits the function β cells and induces 
apoptosis.  The  body  secretes  IL-1Ra  to  counter  the  effect  of  IL-1.  It  is  a  naturally  occurring  
anti-inflammatory  protein  capable  of  inhibiting  both  types  of  IL-1  signaling  and  protecting  the  β  
cells [43–49]. In patients with T2DM it is a common situation that the functional β cell mass is unable 
to compensate for the increasing insulin need due to insulin resistance. In the course of the disease, the 
β  cells  lose  its  ability  to  function,  irrespective  of  the  treatment  given.  In  T2DM  patients  with 
periodontitis, inflammation may have already occurred in the periodontium, leading to a lower level of 
IL-1Ra expression to counter the inflammation. 
3. Experimental Section 
3.1. Collection and Pre-Treatment of the Saliva Samples 
The current study was carried out with the approval of the Ethical Committee (Institutional Review 
Board)  of  the  Faculty  of  Dentistry,  University  of  Malaya  (Ethics  approval  DFOB1003/0034(P)). 
Patients who had been confirmed with T2DM (WHO 1999) from the Diabetic Clinic of the University 
of Malaya Medical Centre and were on regular follow-up for a minimum of 6 months and who gave 
their written consent were enrolled into the study. The subjects, aged between 40 and 60 years, were Int. J. Mol. Sci. 2012, 13  4649 
 
 
screened by BPE/CPI using the WHO probe. Periodontally-healthy T2DM patients (Code 0) and those 
with periodontitis (Codes 3 & 4) were selected. The periodontitis subjects were reassessed and those 
with a minimum of 12 teeth were selected. Patients finally recruited for the study were those with ≥5 
pockets of ≥5 mm probing depth and probing attachment loss of ≥4 mm in at least two different 
quadrants which bled on probing. Periodontal assessments were performed using the Florida Probe. 
Patients were excluded if they fit into any of the following categories: a history of systemic antibiotic 
usage  over  the  previous  4  months;  periodontal  treatment  within  the  past  6  months;  were  current 
smokers;  pregnant,  and  had a cerebrovascular or cardiovascular event  within the past  12 months.  
A single periodontal examiner, a resident in the Department of Periodontology had Kappa agreement 
values >0.81 in his intra-examiner reproducibility study: for plaque (0.88), gingival bleeding (0.86), 
probing pocket depth (0.96) and probing attachment loss (0.96), prior to the study. 
The  saliva  of  10  periodontally  healthy  T2DM  subjects  and  15  selected  T2DM  patients  with 
periodontitis was collected. Volunteers were advised to refrain from eating, drinking, smoking and 
performing any oral hygiene activity for at least 1 hour before saliva collection. During the saliva 
collection, volunteers were advised not to talk or move their tongue in the mouth. Saliva collection was 
usually done in the morning between 9 a.m. and 11 a.m. [24] by spitting into an ice-chilled tube which 
contained  a  complete  protease  inhibitor  cocktail  at  a  final  concentration  recommended  by  the 
manufacturer (Roche Ltd, Basel, Switzerland) [20]. Samples were mixed thoroughly before being kept 
in  an  ice  box  and  transported  to  the  laboratory  for  processing.  The  saliva  samples  were  then 
centrifuged at 14,000 g for 20 minutes at 4 °C  in order to remove any debris, cells and food particles 
present. Aliquots of 500 µL saliva samples were then transferred to smaller tubes and 500 µL of 10% 
of TCA and 10 µL 20 mM DTT in acetone was added to precipitate the protein [20]. Precipitated 
protein  samples  were  stored  at  −80  °C   until  used  in  the  2-DE  analysis.  Analysis  by  2-DE  was 
performed on the 25 saliva samples individually in triplicates giving rise to 75 2-DE gels to be analyzed. 
3.2. First Dimensional Separation—Isoelectric Focusing 
Precipitated protein (140 ug) was dissolved in 500 µL rehydration buffer containing 7 M urea,  
2  M  thiourea,  65  mM  DTT,  4%  CHAPS,  0.5%  IPG  Buffer  and  0.002%  bromophenol  blue  and 
quantified  using  the  Bradford  protein  assay  kit  (Bio-Rad,  Hercules,  CA,  USA)  according  to  the 
manufacturer’s  instructions. The protein solution was  then  applied onto 11 cm  rehydrated precast 
immobiline dry strips with pH 4–7 (GE Healthcare BioSciences, Uppsala, Sweden). The dry strips 
were allowed to rehydrate passively for 12 hours before being subjected to first dimensional separation 
by isoelectric focusing (IEF) using the Bio-Rad Protean IEF system (Bio-Rad, Hercules, CA, USA). 
3.3. Second Dimensional Separation—Polyacrylamide Gel Electrophoresis 
Polyacrylamide gels were prepared as previously described [20]. Second dimensional polyacrylamide 
gel electrophoresis was performed on Bio-Rad Protean II XL Cell (Bio-Rad, Hercules, CA, USA) gel 
tank using the manufacturer’s recommended conditions. 
All of the 75 2-DE gels were then developed and visualized by silver staining [50]. Int. J. Mol. Sci. 2012, 13  4650 
 
 
3.4. Scanning and Analysis of Gel Image 
A GS-800
TM Calibrated Densitometer (Bio-Rad, Hercules, CA, USA) was used to scan and store 
images of the 2-DE gels. Quantity One and PDQuest computer softwares (Bio-Rad, Hercules, CA, 
USA) were used to evaluate protein profiles and perform protein analyses. The percentage volume 
contribution (% vol) of a protein was used to determine proteins that were differentially expressed in 
the saliva. The percentage volume contribution of a protein spot refers to the spot volume of a protein 
expressed as a percentage of the total spot volume of all the salivary proteins that was detected in the 
gel. Data obtained from this method was free from variations attributed to protein loading and staining 
intensity. The protein spots were expressed as mean ±  standard error of means (SEM) and their rate of 
occurrence was also determined. 
3.5. Identification of Saliva Proteins 
Several protein spots of interest were excised from the polyacrylamide gels and identified using 
electrospray  (LC/MS/MS)  mass  spectrometry  with  automatic  database  analysis  (Proteomics 
International,  Perth,  Australia).  After  confirming  the  protein  identity,  other  2-DE  protein  profiles 
obtained were compared visually with those published [20–24]. 
3.6. Statistical Analysis 
Statistical analysis was done using the IBM SPSS statistics, version 19 (IBM Corporation: Chicago, 
IL, USA, 2010). Comparison of the protein profiles between T2DM patients with periodontitis and 
T2DM patients with no periodontitis relates protein changes that are associated with periodontitis. 
Expression  of  saliva  proteins  of  the  two  groups  of  T2DM  patients  were  analyzed  using  the  
Mann-Whitney statistical analysis for significant differences. False discovery rate correction for the p 
value  was  done  using  a  previously  described  method  [51].  Fold  changes  calculation  was  done 
according to the Equation (1): 
) 00 . 1 (
Pr
   changes Fold
um periodonti healthy with Diabetics in protein Similar
tis periodonti with Diabetics in oteins
  (1)  
For the fold changes which are less than 1, the Equation (2) was used:  
) 00 . 1 (
) 00 . 1 (
1
 

changes Fold
changes Fold 
  (2)  
4. Conclusions 
Comparative 2-DE profiling of the saliva samples of T2DM patients with periodontitis and those 
without periodontitis demonstrated the significant differential expression of seven proteins. Whilst the 
expression  of  pIgR,  Arp  3,  CA  VI  and  IL-1Ra  was  down-regulated,  PLS-2,  LEI  and  IGJ  chain 
appeared to be up-regulated in the saliva of the T2DM patients with periodontitis compared to the 
controls. Aside from being involved in the physiological response towards periodontitis, these proteins Int. J. Mol. Sci. 2012, 13  4651 
 
 
have the potential to be used as biomarkers for the prediction of T2DM patients who may be prone  
to periodontitis. 
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